ALMS Alumis Inc. Earnings per share increase in current year

ALMS (Alumis Pharma) - company brandmark

High barriers to entry and patent protection shield Alumis Inc. (ALMS) from the expansion of new players. This chart on GURU.Markets, showing the annual percentage growth of net income per share, demonstrates resilience, with the latest value recorded as -14.00. The diversification of research into autoimmune pathologies mitigates risks, while the strategy focuses on completing the final clinical phases of targeted drugs.

Earnings per share growth in current year: Alumis Inc (ALMS) for 06/29/2024 - 11/12/2026

Financial and market metric breakdowns for Alumis Inc. (ALMS)

- market value and analyst target forecast:
Stock Price Alumis Inc|ALMS - Price Target Chart
- market capitalization data:
Market Value Alumis Pharma|ALMS - Total Company Value
- business book valuation details:
Net Asset Value per Share Alumis|ALMS - Company Book Value|Market Value to Book Value Ratio alumis.com|ALMS - Aggregate Company Assets
- debt and liquidity details:
Debt to Capital Alumis Inc.|ALMS - Long-Term Debt to Capital|Short-Term Indebtedness to Equity alumis.com|ALMS - Company Total Debt|Debts to Book Value Alumis Pharma|ALMS - Company Long-Term Debts|Company Short-Term Debts Alumis|Quick Liquidity alumis.com
- company profitability and valuation multiples indicators:
ALMS - Net Income|Projected Future Earnings Alumis Inc.|ALMS - Price to Earnings Ratio|Projected Price to Earnings Alumis Pharma|ALMS - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Alumis Pharma|ALMS - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Alumis|ALMS - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months alumis.com|ALMS - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Alumis Inc.
Summary company analysis:ALMS Alumis Inc
Signature product of Alumis Inc.

The operational efficiency of Alumis Inc. (ALMS) is directly reflected in the rate of change in net earnings per share compared to the same period last year. This indicator measures fundamental growth in profitability, which, for this biotechnology company utilizing a full outsourcing model for production and trials, minimizes the impact of capital expenditures, as clearly demonstrated by this year-over-year EPS trend.

Direct competitors

Jazz Pharmaceuticals PLC (JAZZ) - Earnings growth in current year|Earnings per share growth in current year Cytokinetics Inc|PTCT: Earnings per share increase in current year|Earnings per share growth in current year Scholar Rock (SRRK)|CNTA - Earnings per share growth rate in current year|Earnings per share growth in current year Dyne Therapeutics DYN|Edgewise Therapeutics Inc - Earnings per share growth in current year|RAPP - Earnings per share growth in current year|Earnings per share growth rate in current year Zevra Corp|CTNM: Earnings growth in current year|Net earnings per share change in current year larimartx.com LRMR|Net earnings per share growth this year CAPR|Earnings per share growth rate in current year Entrada Therapeutics Inc. TRDA|Earnings growth in current year PTHS|Earnings growth in current year medicinova.com (MNOV)|Earnings per share growth in current year Serina Therapeutics, Inc. SER|bioxceltherapeutics.com - Earnings per share growth in current year|PMN: Net earnings per share growth this year|APUS - Earnings growth in current year|aeonbiopharma.com (AEON) - Earnings per share growth in current year|Net earnings per share growth this year NLS Pharmaceutics|BNOX (Bionomics Ltd.) - Earnings growth in current year|fsdpharma.com (HUGE) - Expected net earnings per share growth this year|Earnings per share growth in current year Reata Pharmaceuticals, Inc. (RETA)